HPV Vaccine Effective Against Oral Infections
Vaccine may play role in the primary prevention of HPV-associated oropharyngeal cancer
WEDNESDAY, July 24 (HealthDay News) -- The bivalent human papillomavirus (HPV) 16/18 vaccine is effective against oral infection, according to a study published online July 17 in PLOS ONE.
Rolando Herrero, M.D., Ph.D., from the International Agency for Research on Cancer in Lyon, France, and colleagues randomized (1:1) 7,466 women (aged 18 to 25 years old) to receive either the HPV16/18 vaccine or the hepatitis A vaccine as a control. At the four-year follow-up visit, oral specimens were collected from 5,840 participants (91.9 percent of eligible women) to evaluate vaccine efficacy (VE) against oral infections.
The researchers found that the oral prevalence of identifiable mucosal HPV was relatively low (1.7 percent). At the four-year mark there were 15 prevalent HPV16/18 infections in the control group and one in the vaccine group (VE, 93.3 percent). For prevalent cervical HPV16/18 infection at the same visit, the VE was 72.0 percent. For other oral HPV infections there was no statistically significant protection, although these analyses were limited in their power.
"HPV prevalence four years after vaccination with the ASO4-adjuvanted HPV16/18 vaccine was much lower among women in the vaccine arm compared to the control arm, suggesting that the vaccine affords strong protection against oral HPV16/18 infection, with potentially important implications for prevention of increasingly common HPV-associated oropharyngeal cancer," the authors write.
The vaccine was provided for the trial by GlaxoSmithKline Biologicals. Two authors are named inventors on U.S. Government-owned HPV vaccine patents.
Full Text (http://www.plosone.org/article/info:doi/10.1371/journal.pone.0068329 )